Navigation Links
MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines

at may cause actual results or events to differ materially from those described in the forward-looking statements.

Contact

MIV Therapeutics Inc.
Investor Relations, 604-301-9545, x14
Toll-free: 800-221-5108
Fax: 604-301-9546
investor@mivtherapeutics.com
http://www.mivtherapeutics.com/
or
Trilogy Capital Partners
Financial Communications
Ryon Harms, Toll-free: 800-592-6067
ryon@trilogy-capital.com


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:10/7/2008)...VYVANSE taken once-daily significantly,improved th... Oct. 7 /- Shire plc (LSE: ...aceutical company, today,announced that a study pu...linical Psychiatry found once-daily VYVANSE signif...isorder (ADHD) symptoms in adults within,the first...
(Date:10/7/2008)...swire/ -- Aerovance Inc. today reported,pharmacoki... its Aerovant,inhalation powder that demonstrate g...cy following asthma patients, inhalation of a sing...st of three doses investigated in,Aerovance,s Phas...gin early,next year. Evidence gathered from noncli...
(Date:10/7/2008)...ed in Stage A of Trial Assessing Regimen of Bav...taxel -, TUSTIN, Calif., Oct. 7 /PRNewswire-First... PPHM ), a clinical stage biopharmaceutical,compan...nt of cancer and,hepatitis C virus (HCV) infection... in the first stage of a Phase II trial of bavitux...
(Date:10/6/2008)...wire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq: VRUS...ining the,Company as Vice President of Investor Re...ll be responsible for all investor relations,funct...fficer Kurt,Leutzinger., Most recently, Dr. Smith...lyst at JPMorgan Securities, and has been an analy...
Breaking Medicine Technology:Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 2Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 3CSIRO enlisted to avert global wheat supply crisis 4432 1CSIRO enlisted to avert global wheat supply crisis 4432 2Oregon Based First Pacific Corporation Launches New Integrated 3 D Charting Program for Dentists 25343 1Oregon Based First Pacific Corporation Launches New Integrated 3 D Charting Program for Dentists 25343 2Resolution Health Introduces Womens Health and Wellness Action Campaign 25340 1Resolution Health Introduces Womens Health and Wellness Action Campaign 25340 2Resolution Health Introduces Womens Health and Wellness Action Campaign 25340 3Resolution Health Introduces Womens Health and Wellness Action Campaign 25340 4Tiny molecule helps control blood vessel development UT Southwestern researchers find 25337 1Tiny molecule helps control blood vessel development UT Southwestern researchers find 25337 2
... 23, 2007 /PRNewswire/ -- Researchers at,the Medic...ced the,results of a two-year study, which tested ...s Nerve Stimulation),Therapy(TM) in patients with ...f which Mark S. George, M.D., MUSC Distinguished,P...s is a lead,author, will appear in the April 2007 ...
...enchymal cells in bone marrow supply,leukemic cell...ritical nutrient when it is depleted by the cancer... /PRNewswire/ -- The cancer drug,asparaginase fail...tic leukemia (ALL) because molecules released by c...ect of that drug,according to investigators at St...
Other Medicine Technology:MUSC Research Offers Hope for Those Resistant to Depression,Treatment 2Leukemic Cells Find Safe Haven in Bone Marrow 2Leukemic Cells Find Safe Haven in Bone Marrow 3
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...as good at beating mild to moderate depression as ... comparing five different exercise programs for pe... 50-percent reduction in depressive symptoms amon... like walking on a treadmill three to five times a...
...likely to kill high-risk women compared to women w...ased on findings of a recent study . 8,353 women w...risk because of diabetes or multiple risk factors ...r three years to determine how doctors managed the...
...rchers say girls are affected more than boys. Rese...ifference between girls and boys being diagnosed w...s of conducting a study which aims to establish wh...hy. The study included 307 healthy children 4 or 5...
...to a treatment regimen already consisting of chemo... survival outcomes among women with high-risk brea...udy done between 1979 and 1986, 318 patients were ...herapy or no radiation at all. In a 20-year follow...
Other Medicine News:
Designed to insert eye spheres using spring loaded plunger. Polished finish. Overall length: 125 mm, 4.9 inches.
Size: Large. 24.50 mm by 26.00 mm. Clear lucite. Supplied sterile.
Size: 2.3 x 6.4 x 80 mm. Storz offers the original Scleral Sponge II line designed by Harvey A. Lincoff, M.D. The material is a closed cell sponge which is non-toxic and non-antigenic. Implants are
Size: 5.0 x 80 mm. Storz offers the original Scleral Sponge II line designed by Harvey A. Lincoff, M.D. The material is a closed cell sponge which is non-toxic and non-antigenic. Implants are soft wi
Medicine Products: